Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study

Authors: Simone Scagnoli, Simona Pisegna, Angela Toss, Roberta Caputo, Michelino De Laurentiis, Michela Palleschi, Ugo de Giorgi, Enrico Cortesi, Agnese Fabbri, Alessandra Fabi, Ida Paris, Armando Orlandi, Giuseppe Curigliano, Carmen Criscitiello, Ornella Garrone, Gianluca Tomasello, Giuliana D’Auria, Patrizia Vici, Enrico Ricevuto, Federica Domati, Claudia Piombino, Sara Parola, Roberta Scafetta, Alessio Cirillo, Beatrice Taurelli Salimbeni, Francesca Sofia Di Lisa, Lidia Strigari, Robert Preissner, Maurizio Simmaco, Daniele Santini, Paolo Marchetti, Andrea Botticelli

Source: npj Breast Cancer, Vol 10, Iss 1, Pp 1-10 (2024)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2374-4677

Access URL: https://doaj.org/article/9f47555ab4e54af1bfb2ac3aefc63ec9

Breast and cervical cancer in transgender men: literature review and a case report

Authors: Francesca Sofia Di Lisa, Alice Villa, Lorena Filomeno, Teresa Arcuri, Benito Chiofalo, Giuseppe Sanguineti, Laura Pizzuti, Eriseld Krasniqi, Maddalena Barba, Domenico Sergi, Francesco Lombardo, Francesco Romanelli, Claudio Botti, Giovanni Zoccali, Gennaro Ciliberto, Patrizia Vici

Source: Therapeutic Advances in Medical Oncology, Vol 16 (2024)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1758-8359

Access URL: https://doaj.org/article/0b25398f4cc04772a41b2348d2e1a732

TRF2 as novel marker of tumor response to taxane-based therapy: from mechanistic insight to clinical implication

Authors: Sara Iachettini, Irene Terrenato, Manuela Porru, Serena Di Vito, Angela Rizzo, Carmen D’Angelo, Eleonora Petti, Roberto Dinami, Carmen Maresca, Anna Di Benedetto, Aldo Palange, Antonino Mulè, Angela Santoro, Antonella Palazzo, Paola Fuso, Antonella Stoppacciaro, Patrizia Vici, Lorena Filomeno, Francesca Sofia Di Lisa, Teresa Arcuri, Eriseld Krasniqi, Alessandra Fabi, Annamaria Biroccio, Pasquale Zizza

Source: Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-16 (2024)

Subject Terms: TRF2, Autophagy, Taxanes, Drug sensitivity, TNBC, Predictive marker, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1756-9966

Access URL: https://doaj.org/article/b5288dd001e444b193813380b0f2304e

The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world

Authors: Patrizio Giacomini, Fabio Valenti, Matteo Allegretti, Matteo Pallocca, Francesca De Nicola, Ludovica Ciuffreda, Maurizio Fanciulli, Stefano Scalera, Simonetta Buglioni, Elisa Melucci, Beatrice Casini, Mariantonia Carosi, Edoardo Pescarmona, Elena Giordani, Francesca Sperati, Nicoletta Jannitti, Martina Betti, Marcello Maugeri-Saccà, Fabiana Letizia Cecere, Veronica Villani, Andrea Pace, Marialuisa Appetecchia, Patrizia Vici, Antonella Savarese, Eriseld Krasniqi, Virginia Ferraresi, Michelangelo Russillo, Alessandra Fabi, Lorenza Landi, Gabriele Minuti, Federico Cappuzzo, Massimo Zeuli, Gennaro Ciliberto

Source: Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-12 (2023)

Subject Terms: Molecular tumor board, Tumor DNA (tDNA), Circulating tumor DNA (ctDNA), Next generation sequencing (NGS), Digital PCR (dPCR), Target therapy, Medicine

File Description: electronic resource

Relation: https://doaj.org/toc/1479-5876

Access URL: https://doaj.org/article/8cd52fa220ea4469af2300403ba19259

Author Correction: Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study

Authors: Simone Scagnoli, Simona Pisegna, Angela Toss, Roberta Caputo, Michelino De Laurentiis, Michela Palleschi, Ugo de Giorgi, Enrico Cortesi, Agnese Fabbri, Alessandra Fabi, Ida Paris, Armando Orlandi, Giuseppe Curigliano, Carmen Criscitiello, Ornella Garrone, Gianluca Tomasello, Giuliana D’Auria, Patrizia Vici, Enrico Ricevuto, Federica Domati, Claudia Piombino, Sara Parola, Roberta Scafetta, Alessio Cirillo, Beatrice Taurelli Salimbeni, Francesca Sofia Di Lisa, Lidia Strigari, Robert Preissner, Maurizio Simmaco, Daniele Santini, Paolo Marchetti, Andrea Botticelli

Source: npj Breast Cancer, Vol 10, Iss 1, Pp 1-1 (2024)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2374-4677

Access URL: https://doaj.org/article/16a6bc6a49b04c55b1e7f75ad7375e59

De-Implementation of Axillary Staging and Radiotherapy in Low-Risk Breast Cancer Patients Aged 70–79 Years from Six Italian Cancer Institutes

Authors: Lauro Bucchi, Alessandra Ravaioli, Luigino Dal Maso, Fabio Falcini, Lucia Mangone, Samuele Massarut, Laura Schirosi, Anna Crispo, Patrizia Vici, Silvia Franceschi

Source: Current Oncology, Vol 30, Iss 4, Pp 4177-4184 (2023)

Subject Terms: axillary staging, breast cancer, de-escalation, de-implementation, guidelines, older patient, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.mdpi.com/1718-7729/30/4/318; https://doaj.org/toc/1198-0052; https://doaj.org/toc/1718-7729

Access URL: https://doaj.org/article/cc51827688db4070b1ce6b836bd2b9dd

DARPP-32 and t-DARPP in the development of resistance to anti-HER2 agents. Pre-clinical evidence from the STEP study

Authors: Giulia Bon, Eriseld Krasniqi, Manuela Porru, Lorenzo D'Ambrosio, Stefano Scalera, Marcello Maugeri-Saccà, Francesca Sofia Di Lisa, Lorena Filomeno, Teresa Arcuri, Andrea Botticelli, Daniele Santini, Maria Agnese Fabbri, Giuliana D'Auria, Claudio Pulito, Giovanni Blandino, Caterina Marchiò, Maddalena Barba, Gennaro Ciliberto, Patrizia Vici, Laura Pizzuti

Source: Neoplasia: An International Journal for Oncology Research, Vol 45, Iss , Pp 100937- (2023)

Subject Terms: HER2 positive metastatic breast cancer, Pertuzumab pretreated, Real-world evidence, PPP1R1B, DARPP-32 and t-DARPP, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S1476558623000611; https://doaj.org/toc/1476-5586

Access URL: https://doaj.org/article/f29fae04ef374dc0bbefa7906732c0e1

Rising incidence of late stage breast cancer after COVID-19 outbreak. Real-world data from the Italian COVID-DELAY study

Authors: Giulia Mentrasti, Luca Cantini, Patrizia Vici, Nicola D'Ostilio, Nicla La Verde, Rita Chiari, Vittorio Paolucci, Sonia Crocetti, Chiara De Filippis, Federica Pecci, Francesca Sofia Di Lisa, Donatella Traisci, Maria Silvia Cona, Linda Nicolardi, Laura Pizzuti, Simona Gildetti, Simone Oldani, Arianna Della Mora, Marco Luigi Bruno Rocchi, Rossana Berardi

Source: Breast, Vol 65, Iss , Pp 164-171 (2022)

Subject Terms: Breast cancer, COVID-19, Diagnostic delay, Therapeutic delay, Multidisciplinary discussions, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S0960977622001400; https://doaj.org/toc/1532-3080

Access URL: https://doaj.org/article/5a1c9c5ec8c048d8a0f712de03031afa

Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study

Authors: Nicla La Verde, Giovanna Damia, Ornella Garrone, Daniele Santini, Alessandra Fabi, Mariangela Ciccarese, Daniele Giulio Generali, Martina Nunzi, Elena Poletto, Elisa Ferraris, Elisabetta Cretella, Giuseppa Scandurra, Icro Meattini, Alessandro Stefano Bertolini, Luigi Cavanna, Elena Collovà, Emanuela Romagnoli, Eliana Rulli, Lorenzo Legramandi, Federica Guffanti, Annalisa Bramati, Anna Moretti, Alessandra Cassano, Patrizia Vici, Valter Torri, Gabriella Farina, PAINTER investigators

Source: Breast Cancer Research, Vol 24, Iss 1, Pp 1-12 (2022)

Subject Terms: Breast cancer, Eribulin, Neurotoxicity, Polymorphisms, Peripheral neuropathy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1465-542X

Access URL: https://doaj.org/article/ce3620b6c9374e95a95402fd78331bff

Prognostic value of [18F]-FDG PET/CT in patients with meta-static breast cancer treated with cyclin-dependent inhibitors

Authors: Alessio Annovazzi, Sandra Rea, Daria Maccora, Laura Pizzuti, Gianluigi Ferretti, Patrizia Vici, Federico Cappuzzo, Rosa Sciuto

Source: Frontiers in Oncology, Vol 13 (2023)

Subject Terms: PET-CT scan, fluorodeoxyglucose F18, breast cancer, cyclin-dependent kinase 4, progression-free and overall survival, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2023.1193174/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/34c63118bba74dd5ae45516389f04982

A prospective study assessing the pattern of response of local disease at DCE-MRI after salvage radiotherapy for prostate cancer

Authors: Marta Bottero, Adriana Faiella, Diana Giannarelli, Alessia Farneti, Pasqualina D'Urso, Luca Bertini, Valeria Landoni, Patrizia Vici, Giuseppe Sanguineti

Source: Clinical and Translational Radiation Oncology, Vol 35, Iss , Pp 21-26 (2022)

Subject Terms: Prostate cancer, Salvage radiotherapy, Dynamic contrast enhancement magnetic resonance imaging, Local failure, Medical physics. Medical radiology. Nuclear medicine, R895-920, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2405630822000337; https://doaj.org/toc/2405-6308

Access URL: https://doaj.org/article/93ae6794954c4c6c8005da0310d6597f

Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study

Authors: Agnese Fabbri, Fabrizio Nelli, Andrea Botticelli, Diana Giannarelli, Eleonora Marrucci, Cristina Fiore, Antonella Virtuoso, Simone Scagnoli, Simona Pisegna, Daniele Alesini, Valentina Sini, Armando Orlandi, Alessandra Fabi, Federico Piacentini, Luca Moscetti, Giuliana D’Auria, Teresa Gamucci, Marco Mazzotta, Laura Pizzuti, Patrizia Vici, Elisabetta Cretella, Paola Scavina, Annalisa La Cesa, Mara Persano, Francesco Atzori, Enzo Maria Ruggeri

Source: Frontiers in Oncology, Vol 13 (2023)

Subject Terms: pertuzumab, trastuzumab, breast cancer, neoadjuvant chemotherapy, HER-2 positive, real-world data, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2023.1177681/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/26649e667aa0456fbd64724a36c65d33

Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study

Authors: Francesca Sofia Di Lisa, Eriseld Krasniqi, Laura Pizzuti, Maddalena Barba, Katia Cannita, Ugo De Giorgi, Fulvio Borella, Jennifer Foglietta, Anna Cariello, Antonella Ferro, Elisa Picardo, Marco Mitidieri, Valentina Sini, Simonetta Stani, Giuseppe Tonini, Daniele Santini, Nicla La Verde, Anna Rita Gambaro, Antonino Grassadonia, Nicola Tinari, Ornella Garrone, Giuseppina Sarobba, Lorenzo Livi, Icro Meattini, Giuliana D’Auria, Matteo Vergati, Teresa Gamucci, Mirco Pistelli, Rossana Berardi, Emanuela Risi, Francesco Giotta, Vito Lorusso, Lucia Rinaldi, Salvatore Artale, Marina Elena Cazzaniga, Fable Zustovich, Federico Cappuzzo, Lorenza Landi, Rosalba Torrisi, Simone Scagnoli, Andrea Botticelli, Andrea Michelotti, Beatrice Fratini, Rosa Saltarelli, Ida Paris, Margherita Muratore, Alessandra Cassano, Lorenzo Gianni, Valeria Gaspari, Enzo Maria Veltri, Federica Zoratto, Elena Fiorio, Maria Agnese Fabbri, Marco Mazzotta, Enzo Maria Ruggeri, Rebecca Pedersini, Maria Rosaria Valerio, Lorena Filomeno, Mauro Minelli, Paola Scavina, Mimma Raffaele, Antonio Astone, Roy De Vita, Marcello Pozzi, Ferdinando Riccardi, Filippo Greco, Luca Moscetti, Monica Giordano, Marcello Maugeri-Saccà, Alessandro Zennaro, Claudio Botti, Fabio Pelle, Sonia Cappelli, Flavia Cavicchi, Enrico Vizza, Giuseppe Sanguineti, Federica Tomao, Enrico Cortesi, Paolo Marchetti, Silverio Tomao, Iolanda Speranza, Isabella Sperduti, Gennaro Ciliberto, Patrizia Vici

Source: Frontiers in Oncology, Vol 13 (2023)

Subject Terms: triple negative breast cancer, neoadjuvant treatment, residual tumors, adjuvant capecitabine, treatment discontinuation, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2023.1152123/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/9054ef5212d94639a5488c4656e59bc0

Corrigendum: Cross-resistance among sequential cancer therapeutics: An emerging issue

Authors: Rossella Loria, Patrizia Vici, Francesca Sofia Di Lisa, Silvia Soddu, Marcello Maugeri-Saccà, Giulia Bon

Source: Frontiers in Oncology, Vol 12 (2022)

Subject Terms: targeted-therapy, cancer therapeutics resistance, cross-resistance, sequential therapeutics, personalized oncology, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2022.1063651/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/aff168bbbe72487db23a9d7d628fc536

Stereotactic partial breast irradiation in primary breast cancer: A comprehensive review of the current status and future directions

Authors: Silvia Takanen, Paola Pinnarò, Ilaria Farina, Francesca Sperati, Claudio Botti, Patrizia Vici, Antonella Soriani, Laura Marucci, Giuseppe Sanguineti

Source: Frontiers in Oncology, Vol 12 (2022)

Subject Terms: breast cancer, stereotactic partial breast radiotherapy, local toxicity, SBRT, breast cosmesis, APBI, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2022.953810/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/95bebebc99ac4362818a5eda740daf22

Neutrophil extracellular traps in cancer: not only catching microbes

Authors: Livia Ronchetti, Nouha Setti Boubaker, Maddalena Barba, Patrizia Vici, Aymone Gurtner, Giulia Piaggio

Source: Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-9 (2021)

Subject Terms: citH3, PAD4, Chemokine receptors, Neutrophils, PD-L1 inhibitors, NET, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1756-9966

Access URL: https://doaj.org/article/483b4ecc25c143c5979a21c6799e8e9d

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial

Authors: Laura Pizzuti, Maddalena Barba, Marco Mazzotta, Eriseld Krasniqi, Marcello Maugeri-Saccà, Teresa Gamucci, Rossana Berardi, Lorenzo Livi, Corrado Ficorella, Clara Natoli, Enrico Cortesi, Daniele Generali, Nicla La Verde, Alessandra Cassano, Emilio Bria, Luca Moscetti, Andrea Michelotti, Vincenzo Adamo, Claudio Zamagni, Giuseppe Tonini, Domenico Sergi, Daniele Marinelli, Giancarlo Paoletti, Silverio Tomao, Andrea Botticelli, Paolo Marchetti, Nicola Tinari, Antonino Grassadonia, Maria Rosaria Valerio, Rosanna Mirabelli, Maria Agnese Fabbri, Nicola D’Ostilio, Enzo Veltri, Domenico Corsi, Ornella Garrone, Ida Paris, Giuseppina Sarobba, Icro Meattini, Mirco Pistelli, Francesco Giotta, Vito Lorusso, Carlo Garufi, Antonio Russo, Marina Cazzaniga, Pietro Del Medico, Mario Roselli, Angela Vaccaro, Letizia Perracchio, Anna di Benedetto, Theodora Daralioti, Isabella Sperduti, Ruggero De Maria, Angelo Di Leo, Giuseppe Sanguineti, Gennaro Ciliberto, Patrizia Vici

Source: Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)

Subject Terms: Medicine, Science

File Description: electronic resource

Relation: https://doaj.org/toc/2045-2322

Access URL: https://doaj.org/article/480280eb7ab4458fa7a0a13c1dcceb2c

PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy

Authors: Francesco Cognetti, Riccardo Masetti, Alessandra Fabi, Giulia Bianchi, Donatella Santini, Alessia Rognone, Giovanna Catania, Domenico Angelucci, Giuseppe Naso, Mario Giuliano, Lucia Vassalli, Patrizia Vici, Giovanni Scognamiglio, Daniele Generali, Alberto Zambelli, Marco Colleoni, Corrado Tinterri, Francesco Scanzi, Leonardo Vigna, Paola Scavina, Teresa Gamucci, Emilia Marrazzo, Angelo Fedele Scinto, Rossana Berardi, Maria Agnese Fabbri, Graziella Pinotti, Daniela Franco, Daniela Andreina Terribile, Giuseppe Tonini, Daniela Cianniello, Sandro Barni

Source: npj Breast Cancer, Vol 7, Iss 1, Pp 1-8 (2021)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2374-4677

Access URL: https://doaj.org/article/a0a882fd09a64018b374c4f2f70cd885

Tgf-β1 transcriptionally promotes 90K expression: possible implications for cancer progression

Authors: Antonino Grassadonia, Vincenzo Graziano, Sara Pagotto, Angelo Veronese, Cesidio Giuliani, Marco Marchisio, Paola Lanuti, Michele De Tursi, Maurizia D’Egidio, Pietro De Marino, Davide Brocco, Patrizia Vici, Laura De Lellis, Alessandro Cama, Clara Natoli, Nicola Tinari

Source: Cell Death Discovery, Vol 7, Iss 1, Pp 1-13 (2021)

Subject Terms: Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, Cytology, QH573-671

File Description: electronic resource

Relation: https://doaj.org/toc/2058-7716

Access URL: https://doaj.org/article/5fc24b252ab84a38bacd5f4f58aebc3f

Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study

Authors: Giulia Bon, Laura Pizzuti, Valentina Laquintana, Rossella Loria, Manuela Porru, Caterina Marchiò, Eriseld Krasniqi, Maddalena Barba, Marcello Maugeri-Saccà, Teresa Gamucci, Rossana Berardi, Lorenzo Livi, Corrado Ficorella, Clara Natoli, Enrico Cortesi, Daniele Generali, Nicla La Verde, Alessandra Cassano, Emilio Bria, Luca Moscetti, Andrea Michelotti, Vincenzo Adamo, Claudio Zamagni, Giuseppe Tonini, Giacomo Barchiesi, Marco Mazzotta, Daniele Marinelli, Silverio Tomao, Paolo Marchetti, Maria Rosaria Valerio, Rosanna Mirabelli, Antonio Russo, Maria Agnese Fabbri, Nicola D’Ostilio, Enzo Veltri, Domenico Corsi, Ornella Garrone, Ida Paris, Giuseppina Sarobba, Francesco Giotta, Carlo Garufi, Marina Cazzaniga, Pietro Del Medico, Mario Roselli, Giuseppe Sanguineti, Isabella Sperduti, Anna Sapino, Ruggero De Maria, Carlo Leonetti, Angelo Di Leo, Gennaro Ciliberto, Rita Falcioni, Patrizia Vici

Source: Journal of Experimental & Clinical Cancer Research, Vol 39, Iss 1, Pp 1-14 (2020)

Subject Terms: HER2+ breast cancer, Trastuzumab/pertuzumab blockade, T-DM1 efficacy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1756-9966

Access URL: https://doaj.org/article/4d34ed52da98405db47bb21f0f6da119